The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.10 - Manufacture of basic pharmaceutical products
100 jobs Number of planned job creations
Announcement Date
11 February 2015
Employment effect (start)
Foreseen end date
Description
The multinational producer of pharmaceutical products, Pfizer, has invested 75 million euro in a production unit creating sterile doses of the pneumococcal vaccine Prevenar 13 at its Puurs facility, creating 100 extra jobs. Employment here has grown from 1,100 employees in 2010 to a scheduled 1,600 employees at the end of 2016.
The managing director indicated that one of the attractions for the US company to invest in Puurs has been the good technical training of employees. The production of this specific vaccine was done to date in the United States.
Sources
11 February 2015: De Standaard
Citation
Eurofound (2015), Pfizer, Business expansion in Belgium, factsheet number 78607, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/78607.